Public Companies
Cybin Officially Owns Small Pharma: Plans For New ‘International Leader’ In Psychedelic Therapeutics
Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement. Following their…
-
Psilocybin7 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics6 days ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics7 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Law & Regulation6 days ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics6 days ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics7 days ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin7 days ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics7 days ago
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research